Crown Bioscience, a JSR Life Sciences company and global CRO, specializes in oncology and immuno-oncology drug discovery and development.
Joined June 2010
- Tweets 10,082
- Following 555
- Followers 11,001
- Likes 710
7,025 Photos and videos
How can PDX/PDXO platforms enable ADC therapies?
Our AACR 2026 Poster reveals how in a TNBC patient with acquired resistance to Sacituzumab Govitecan this approach supported payload screening, predicted in vivo efficacy and identified alternative payloads.
hubs.la/Q04l971L0
37
It’s not just about having the right tools; it’s about having the right partner. Companies collaborate with us because of our proven expertise and deep understanding of what it takes to accelerate drug discovery.
See unfiltered feedback from our clients: hubs.la/Q04l1B_r0
13
This blog post outlines the key advantages and disadvantages of humanized mouse models to help researchers determine the right starting point for a study. Read now: hubs.la/Q04kRWqF0
10
In this webinar, we reveal how clinically relevant in vitro and in vivo prostate cancer models are advancing treatment for one of the most diagnosed cancers in men.
hubs.la/Q04kCQQf0
17
AACR 2026 made one thing clear: innovation in oncology drug development is no longer incremental.
In the latest CrownCast episode, our experts share their take on this year’s conference. Watch now: hubs.la/Q04kk1pY0
35
Our AACR 2026 Poster shows how tracking the Drug-to-Antibody Ratio (DAR) with a robust ADC testing platform provides data that’s critical for de-risking drug development.
hubs.la/Q04kg7sK0
1
33
With flexible licensing options for datasets spanning WES, RNA-Seq, proteomics and more, accessing OMICS and SoC datasets has never been easier.
Discover data licensing opportunities from our industry-leading PDX and organoid models: hubs.la/Q04k0Xnr0
34
We’re pleased to launch our Small Panel Bone Marrow Niche platform.
The Small Panel format reduces study conditions from 30 to fewer than 15, helping researchers access a more flexible and resource-efficient approach for hematological cancer studies.
hubs.la/Q04jTrnb0
20
Our unified approach to biomarker testing – spanning validated assays, high-quality biospecimens, and integrated data analysis – brings stronger insights, reduced risk, and more confident decision-making to your clinical biomarker strategy.
hubs.la/Q04jw-Fd0
25
Clinical biomarker strategies are essential for guiding drug development, but their complexity can delay insights and limit impact.
Discover how our integrated biomarker services support more informed clinical decisions: hubs.la/Q04jx6jh0
26
PA20006B is a primary-site pancreatic organoid model derived from a patient sample.
Recapitulate key characteristics of parental tumors and support more informed evaluation of tumor biology and therapeutic response.
Explore PA20006B and more: hubs.la/Q04jrqK50
41
Looking for the best customer experience available in the industry? Explore our monthly Customer Satisfaction Report: hubs.la/Q04h_XdC0
17
Our AACR 2026 Poster demonstrates how organoid fibroblast co-culture systems, combined with high-content imaging (HCI), improve the assessment of tumor killing, immune infiltration and resistance mechanisms. hubs.la/Q04hSGh-0
44
Crown Bioscience will be attending the 74th ASMS Conference on Mass Spectrometry and Allied Topics in San Diego.
Schedule a meeting: hubs.la/Q04htm9m0
33
In this on-demand webinar, Rekha Pal, PhD, provides a masterclass in integrating pharmacokinetics (PK) with pharmacodynamics (PD) to transform raw data into a roadmap for candidate success.
Watch now: hubs.la/Q04hsGqq0
54
This study highlights how advanced organoid-based 3D in vitro platforms can improve the translational relevance of immunotherapy testing by more accurately modeling the tumor microenvironment.
hubs.la/Q04h4dQD0
2
2
181
Did you know skin cancer is the most common type of cancer in the US? ¹ This Skin Cancer Awareness Month, we’re highlighting research advancements in melanoma cancer treatment.
cancer.gov/types/skin
¹hubs.la/Q04h49LW0
2
20
From target validation and biomarker discovery to hypothesis testing and AI/ML model development, Crown Bioscience Data Licensing empowers confident decision-making during oncology drug discovery.
Discover more: hubs.la/Q04gyhBn0
25
Crown Bioscience’s Model of the Month, CR9831, is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC (ABBV-400).
Partner with us to access models that mirror today’s clinical landscape.
hubs.la/Q04grlfJ0
62
Our unified approach to biomarker testing – spanning validated assays, high-quality biospecimens, and integrated data analysis – brings stronger insights, reduced risk, and more confident decision-making to your clinical biomarker strategy.
hubs.la/Q04g2ZRL0
15